表紙
市場調查報告書

電力藥學 (electroceuticals) :技術和全球市場

Electroceuticals: Technologies and Global Markets

出版商 BCC Research 商品編碼 916668
出版日期 內容資訊 英文 129 Pages
訂單完成後即時交付
價格
電力藥學 (electroceuticals) :技術和全球市場 Electroceuticals: Technologies and Global Markets
出版日期: 2019年11月08日內容資訊: 英文 129 Pages
簡介

全球電力藥學市場,預計從2019年的276億美元到2024年擴大到392億美元,最近7.3%的年複合成長率預計。

本報告提供全球電力藥學 (electroceuticals) 市場相關調查,全球市場、技術概要,世界市場趨勢分析與年複合成長率預測,考慮電力藥學藥物為基礎的治療替代的理由相關的討論,影響全球市場成長的要素,及主要企業簡介等彙整。

第1章 簡介

第2章 摘要、亮點

第3章 市場、技術背景

  • 市場定義
  • 市場成長的推動要素
  • 市場成長的阻礙因素
  • 機會

第4章 市場分析:各技術類型

  • 心臟去顫器及心臟心律調節器
  • 深部腦刺激器 (DBS)
  • 脊髓刺激設備 (SCS)
  • 迷走神經刺激設備
  • 助聽器和人工電子耳
  • 其他 (薦骨神經刺激器,經皮電刺激設備)

第5章 市場分析:各終端用戶

  • 醫院、診所
  • 居家醫療、其他

第6章 市場分析:各地區

  • 北美
  • 歐洲
  • 亞太地區
  • 南美

第7章 專利檢討/新的發展

第8章 市場機會分析

  • 主要製造廠商
  • 主要企業
    • Abbott Laboratories Inc.
    • Boston Scientific Corp.
    • Demant A/S
    • Medtronic PLC
    • Sonova Holding AG
  • 電力藥學的市售前核准 (PMA)

第9章 企業簡介

  • ABBOTT LABORATORIES INC.
  • ADVANCED BIONICS AG
  • ALEVA NEUROTHERAPEUTICS SA
  • AXONICS MODULATION TECHNOLOGIES INC.
  • BIOELECTRONICS CORP.
  • BIOTRONIK INC.
  • BOSTON SCIENTIFIC CORP.
  • CALA HEALTH INC.
  • COCHLEAR CORP.
  • DEMANT A/S
  • EDWARDS LIFESCIENCES CORP.
  • ELECTROCORE INC.
  • FUNCTIONAL NEUROMODULATION LTD.
  • GLAXOSMITHKLINE PLC
  • GETINGE AB
  • GN STORE NORD
  • HANGZHOU NUROTRON BIOTECHNOLOGY CO. LTD.
  • LEPU MEDICAL TECHNOLOGY (BEIJING) CO. LTD.
  • LIVANOVA PLC
  • MEDTRONIC PLC
  • NEUROPACE, INC.
  • NEVRO CORP.
  • NUVECTRA CORP.
  • SECOND SIGHT MEDICAL PRODUCTS INC.
  • SIVANTOS PTE. LTD.
  • SONOVA AG
  • STARKEY HEARING TECHNOLOGIES
  • STIMWAVE LLC
  • Terumo Corporation
  • ZOLL MEDICAL CORP.
目錄
Product Code: MDS001A

Report Highlights:

The global market for electroceuticals should grow from $27.6 billion in 2019 to $39.2 billion by 2024 at a compound annual growth rate (CAGR) of 7.3% for the period of 2019-2024.

Hearing aids and cochlear implants as a segment of the global market for electroceuticals should grow from $10.6 billion in 2019 to $15.6 billion by 2024 at a compound annual growth rate (CAGR) of 8.1% for the period of 2019-2024.

Spinal cord stimulator as a segment of the global market for electroceuticals should grow from $3.8 billion in 2019 to $6.2 billion by 2024 at a compound annual growth rate (CAGR) of 10.6% for the period of 2019-2024.

Report Scope:

This report provides a comprehensive summary of electroceutical technologies and global markets, along with detailed profiles of key market players, a revenue product portfolio and recent activities. This report analyzes trends and dynamics, including drivers, limitations, challenges and opportunities. This report discusses strategies adopted by emerging market players, with recommendations for new market entrants. This research study discusses historical, current and potential market size. This report will help market players and new entrants make informed decisions about the production and export of goods and services. Organizations, distributors and exporters should find the information about market development and trends useful. This study segments the market on the basis of applications and end use. Geographic market analysis is provided for all major segments.

Report Includes:

  • 29 data tables and 24 additional tables
  • An overview of global markets and technologies for electroceuticals
  • Analyses of global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024
  • Discussion on why electroceuticals are considered as an alternative to drug-based remedies
  • Identification of endogenous and exogenous factors that are impacting the global market growth
  • Coverage of several diseases such as epilepsy, cardiovascular diseases, rheumatoid arthritis and diabetes and their treatment using electroceuticals
  • Information on RecoveryRx medical device, which is used for the treatment of postoperative pain of opioid/NSAID therapy
  • Comprehensive profiles of leading companies in the industry, including Abbott Laboratories Inc., Biotronik Inc., Cochlear Corp., GlaxoSmithKline Plc and Sonova AG

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Market and Technology Background

  • Market Definition
    • North America
    • Cardioverter Defibrillators and Cardiac Pacemaker Segment
    • R&D
    • Public Access Defibrillators (PAD)
    • Asia Pacific
    • Battery Technology
  • Factors Driving Market Growth
    • CVD
    • Product Launch
    • Growing Geriatric Population
  • Factors Restraining Market Growth
    • Alternative Drugs: Treatment of Arrhythmia
    • Stringent Government Regulations
    • Hackable Pacemakers
    • Low Awareness
  • Opportunities
    • Growing Healthcare Expenditures

Chapter 4: Market Breakdown by Technology Type

  • Cardioverter Defibrillators and Cardiac Pacemakers
  • Deep Brain Stimulators (DBS)
  • Spinal Cord Stimulators (SCS)
  • Vagus Nerve Stimulators
  • Hearing Aids and Cochlear Implants
  • Others (Sacral Nerve Stimulators, Transcutaneous Electrical Nerve Stimulators)

Chapter 5: Market Breakdown by End User

  • Hospitals and Clinics
  • Homecare and Others

Chapter 6: Market Breakdown by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Rest of Asia Pacific
    • Rest of The World
  • Latin America
    • The Middle East and Africa

Chapter 7: Patent Review/New Developments

Chapter 8: Analysis of Market Opportunities

  • Key Manufacturers
  • Key Players
    • Abbott Laboratories Inc.
    • Boston Scientific Corp.
    • Demant A/S
  • Medtronic PLC
    • Sonova Holding AG
  • Premarket Approval (PMA) Of Electroceuticals

Chapter 9: Company Profiles

  • ABBOTT LABORATORIES INC.
  • ADVANCED BIONICS AG
  • ALEVA NEUROTHERAPEUTICS SA
  • AXONICS MODULATION TECHNOLOGIES INC.
  • BIOELECTRONICS CORP.
  • BIOTRONIK INC.
  • BOSTON SCIENTIFIC CORP.
  • CALA HEALTH INC.
  • COCHLEAR CORP.
  • DEMANT A/S
  • EDWARDS LIFESCIENCES CORP.
  • ELECTROCORE INC.
  • FUNCTIONAL NEUROMODULATION LTD.
  • GLAXOSMITHKLINE PLC
  • GETINGE AB
  • GN STORE NORD
  • HANGZHOU NUROTRON BIOTECHNOLOGY CO. LTD.
  • LEPU MEDICAL TECHNOLOGY (BEIJING) CO. LTD.
  • LIVANOVA PLC
  • MEDTRONIC PLC
  • NEUROPACE, INC.
  • NEVRO CORP.
  • NUVECTRA CORP.
  • SECOND SIGHT MEDICAL PRODUCTS INC.
  • SIVANTOS PTE. LTD.
  • SONOVA AG
  • STARKEY HEARING TECHNOLOGIES
  • STIMWAVE LLC
  • TERUMO CORP.
  • ZOLL MEDICAL CORP.

List of Tables

  • Summary Table: Global Market for Electroceuticals, by Product, Through 2024
    • Table 1: Medications for Heart Dysfunction
    • Table 2: Global Market for Electroceuticals, by Product, Through 2024
    • Table 3: Global Market for Cardioverter Defibrillators and Cardiac Pacemaker, by Region, Through 2024
    • Table 4: Global Market for Cardioverter Defibrillators and Cardiac Pacemakers, by Product, Through 2024
    • Table 5: U.S. FDA Product Classification: Defibrillators
    • Table 6: U.S. FDA Pacemaker Product Classification
    • Table 7: Global Market for Deep Brain Stimulators, by Region, Through 2024
    • Table 8: U.S. FDA Neurostimulator Product Classification, 2019
    • Table 9: Global Market for Spinal Cord Stimulators, by Region, Through 2024
    • Table 10: Global Market for Vagus Nerve Stimulators, by Region, Through 2024
    • Table 11: Global Market for Hearing Aids and Cochlear Implants, by Region, Through 2024
    • Table 12: Global Market for Hearing Aids and Cochlear Implants, by Product, Through 2024
    • Table 13: U.S. FDA Cochlear Implant Product Classification
    • Table 14: Global Market for Other Products, by Region, Through 2024
    • Table 15: Global Market for Electroceuticals, by End User, Through 2024
    • Table 16: Global Market for Hospitals and Clinics, by Region, Through 2024
    • Table 17: Hospitals with Notable Services
    • Table 18: Global Market for Homecare and Others, by Region, Through 2024
    • Table 19: Cardiac Devices
    • Table 20: Global Market for Electroceuticals, by Region, Through 2024
    • Table 21: North American Market for Electroceuticals, by Country, Through 2024
    • Table 22: North American Market for Electroceuticals, by Product, Through 2024
    • Table 23: North American Market for Electroceuticals, by End User, Through 2024
    • Table 24: European Market for Electroceuticals, by Country, Through 2024
    • Table 25: European Market for Electroceuticals, by Product, Through 2024
    • Table 26: European Market for Electroceuticals, by End User, Through 2024
    • Table 27: European Reimbursement
    • Table 28: CE Mark Approval: Electroceuticals Devices
    • Table 29: Heart Disease Statistics, UK, 2016
    • Table 30: Asia-Pacific Market for Electroceuticals, by Country, Through 2024
    • Table 31: Asia-Pacific Market for Electroceuticals, by Product, Through 2024
    • Table 32: Asia-Pacific Market for Electroceuticals, by End User, Through 2024
    • Table 33: China's Medical Device Regulations
    • Table 34: Medical Devices Approved in Japan, FY 2018 and FY 2019
    • Table 35: Rest of The World Market for Electroceuticals, by Product, Through 2024
    • Table 36: Rest of The World Market for Electroceuticals, by End User, Through 2024
    • Table 37: New Products and Technologies
    • Table 38: Patents by Category, Jan. 2017-Aug. 2019
    • Table 39: Patents by Key Players, Jan. 2017-Aug. 2019
    • Table 40: Notable Patents: U.S., Jan. 2017-Aug. 2018
    • Table 41: Notable Patents: Europe, Jan. 2017-Aug. 2018
    • Table 42: Notable Patents: Japan, Jan. 2017-Aug. 2018
    • Table 43: Abbott Laboratories Inc. Divisions, 2018
    • Table 44: Boston Scientific Corp.: Products and Models
    • Table 45: Demant's Hearing Solutions
    • Table 46: Demant's R&D Expenses, 2017 and 2018
    • Table 47: Medtronic Plc: R&D Expenses, 2017 and 2018
    • Table 48: Sonova Holding AG: Segments and Brands
    • Table 49: U.S. FDA PMA for Defibrillators, Jan. 2019-July 2019
    • Table 50: U.S. FDA PMA for Pacemakers, Jan. 2019-July 2019
    • Table 51: U.S. FDA PMA for Cochlear Implants, Jan. 2019-July 2019
    • Table 52: U.S. FDA PMA for Neuro Stimulators, Jan. 2019-July 2019

List of Figures

  • Summary Figure: Global Market for Electroceuticals, by Product, 2018-2024
    • Figure 1: Fatalities from CVD: U.S., 2017
    • Figure 2: Projected Global Population, Aged 60 and Above, 1990-2100
    • Figure 3: Defibrillator Awareness: U.S., 2017
    • Figure 4: Healthcare Expenditure: U.S., 1970-2017
    • Figure 5: Healthcare Expenditure Per Capita: Asia Pacific, 2010 and 2016
    • Figure 6: Pacemakers
    • Figure 7: Global Incidence of Parkinson's Disease, 2013-2017
    • Figure 8: Spinal Cord Stimulator: Parts/Functions
    • Figure 9: Global Incidence of Epilepsy, 2013-2017
    • Figure 10: Hearing Impairment Stages
    • Figure 11: Global Prevalence of Age-Related and Other Hearing Loss, 2013-2017
    • Figure 12: European Medical Device Market Based on Manufacturer Prices, by Country, 2017
    • Figure 13: Hearing Loss Prevalence in UK, 2009-2018
    • Figure 14: Anovum under European Hearing Instrument Manufacturers Association
    • Figure 15: Incidence of Parkinson's Disease, Germany, 2013-2017
    • Figure 16: Ischemic Heart Disease, 2012-2017
    • Figure 17: China's Age-Related and Other Hearing Loss
    • Figure 18: Indian Medical Device Market, by Segment, 2016
    • Figure 19: India's Ischemic Heart Disease
    • Figure 20: Japan's Ischemic Heart Disease
    • Figure 21: Age-Related and Other Hearing Loss, 2012-2017
    • Figure 22: Middle East's Prevalence of Various Diseases, 2017
    • Figure 23: Abbott Laboratories Inc.: Strategic Priorities
    • Figure 24: Demant: Global Revenue, by Region, 2018
    • Figure 25: Demant: Global Revenue, by Market Segment, 2018
    • Figure 26: Medtronic: Global Revenue Share, by Segment, 2017
    • Figure 27: Sonova Holding AG: Competitive Strengths